2024-04-232025-03-312025-03-31false06815886ORAL IMPLANTS LIMITED2025-09-30falseiso4217:GBPxbrli:pure068158862024-04-22068158862025-03-31068158862024-04-232025-03-31068158862023-08-31068158862024-04-22068158862023-09-012024-04-2206815886bus:SmallEntities2024-04-232025-03-3106815886bus:AuditExempt-NoAccountantsReport2024-04-232025-03-3106815886bus:FullAccounts2024-04-232025-03-3106815886bus:PrivateLimitedCompanyLtd2024-04-232025-03-3106815886core:WithinOneYear2025-03-3106815886core:AfterOneYear2025-03-3106815886core:WithinOneYear2024-04-2206815886core:AfterOneYear2024-04-2206815886core:ShareCapital2025-03-3106815886core:SharePremium2025-03-3106815886core:RevaluationReserve2025-03-3106815886core:OtherReservesSubtotal2025-03-3106815886core:RetainedEarningsAccumulatedLosses2025-03-3106815886core:ShareCapital2024-04-2206815886core:SharePremium2024-04-2206815886core:RevaluationReserve2024-04-2206815886core:OtherReservesSubtotal2024-04-2206815886core:RetainedEarningsAccumulatedLosses2024-04-2206815886core:LandBuildings2025-03-3106815886core:PlantMachinery2025-03-3106815886core:Vehicles2025-03-3106815886core:FurnitureFittings2025-03-3106815886core:OfficeEquipment2025-03-3106815886core:NetGoodwill2025-03-3106815886core:IntangibleAssetsOtherThanGoodwill2025-03-3106815886core:ListedExchangeTraded2025-03-3106815886core:UnlistedNon-exchangeTraded2025-03-3106815886core:LandBuildings2024-04-2206815886core:PlantMachinery2024-04-2206815886core:Vehicles2024-04-2206815886core:FurnitureFittings2024-04-2206815886core:OfficeEquipment2024-04-2206815886core:NetGoodwill2024-04-2206815886core:IntangibleAssetsOtherThanGoodwill2024-04-2206815886core:ListedExchangeTraded2024-04-2206815886core:UnlistedNon-exchangeTraded2024-04-2206815886core:LandBuildings2024-04-232025-03-3106815886core:PlantMachinery2024-04-232025-03-3106815886core:Vehicles2024-04-232025-03-3106815886core:FurnitureFittings2024-04-232025-03-3106815886core:OfficeEquipment2024-04-232025-03-3106815886core:NetGoodwill2024-04-232025-03-3106815886core:IntangibleAssetsOtherThanGoodwill2024-04-232025-03-3106815886core:ListedExchangeTraded2024-04-232025-03-3106815886core:UnlistedNon-exchangeTraded2024-04-232025-03-3106815886core:MoreThanFiveYears2024-04-232025-03-3106815886core:Non-currentFinancialInstruments2025-03-3106815886core:Non-currentFinancialInstruments2024-04-2206815886dpl:CostSales2024-04-232025-03-3106815886dpl:DistributionCosts2024-04-232025-03-3106815886core:LandBuildings2024-04-232025-03-3106815886core:PlantMachinery2024-04-232025-03-3106815886core:Vehicles2024-04-232025-03-3106815886core:FurnitureFittings2024-04-232025-03-3106815886core:OfficeEquipment2024-04-232025-03-3106815886dpl:AdministrativeExpenses2024-04-232025-03-3106815886core:NetGoodwill2024-04-232025-03-3106815886core:IntangibleAssetsOtherThanGoodwill2024-04-232025-03-3106815886dpl:GroupUndertakings2024-04-232025-03-3106815886dpl:ParticipatingInterests2024-04-232025-03-3106815886dpl:GroupUndertakingscore:ListedExchangeTraded2024-04-232025-03-3106815886core:ListedExchangeTraded2024-04-232025-03-3106815886dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-04-232025-03-3106815886core:UnlistedNon-exchangeTraded2024-04-232025-03-3106815886dpl:CostSales2023-09-012024-04-2206815886dpl:DistributionCosts2023-09-012024-04-2206815886core:LandBuildings2023-09-012024-04-2206815886core:PlantMachinery2023-09-012024-04-2206815886core:Vehicles2023-09-012024-04-2206815886core:FurnitureFittings2023-09-012024-04-2206815886core:OfficeEquipment2023-09-012024-04-2206815886dpl:AdministrativeExpenses2023-09-012024-04-2206815886core:NetGoodwill2023-09-012024-04-2206815886core:IntangibleAssetsOtherThanGoodwill2023-09-012024-04-2206815886dpl:GroupUndertakings2023-09-012024-04-2206815886dpl:ParticipatingInterests2023-09-012024-04-2206815886dpl:GroupUndertakingscore:ListedExchangeTraded2023-09-012024-04-2206815886core:ListedExchangeTraded2023-09-012024-04-2206815886dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-09-012024-04-2206815886core:UnlistedNon-exchangeTraded2023-09-012024-04-2206815886core:NetGoodwill2025-03-3106815886core:IntangibleAssetsOtherThanGoodwill2025-03-3106815886core:LandBuildings2025-03-3106815886core:PlantMachinery2025-03-3106815886core:Vehicles2025-03-3106815886core:FurnitureFittings2025-03-3106815886core:OfficeEquipment2025-03-3106815886core:AfterOneYear2025-03-3106815886core:WithinOneYear2025-03-3106815886core:ListedExchangeTraded2025-03-3106815886core:UnlistedNon-exchangeTraded2025-03-3106815886core:ShareCapital2025-03-3106815886core:SharePremium2025-03-3106815886core:RevaluationReserve2025-03-3106815886core:OtherReservesSubtotal2025-03-3106815886core:RetainedEarningsAccumulatedLosses2025-03-3106815886core:NetGoodwill2024-04-2206815886core:IntangibleAssetsOtherThanGoodwill2024-04-2206815886core:LandBuildings2024-04-2206815886core:PlantMachinery2024-04-2206815886core:Vehicles2024-04-2206815886core:FurnitureFittings2024-04-2206815886core:OfficeEquipment2024-04-2206815886core:AfterOneYear2024-04-2206815886core:WithinOneYear2024-04-2206815886core:ListedExchangeTraded2024-04-2206815886core:UnlistedNon-exchangeTraded2024-04-2206815886core:ShareCapital2024-04-2206815886core:SharePremium2024-04-2206815886core:RevaluationReserve2024-04-2206815886core:OtherReservesSubtotal2024-04-2206815886core:RetainedEarningsAccumulatedLosses2024-04-2206815886core:NetGoodwill2023-08-3106815886core:IntangibleAssetsOtherThanGoodwill2023-08-3106815886core:LandBuildings2023-08-3106815886core:PlantMachinery2023-08-3106815886core:Vehicles2023-08-3106815886core:FurnitureFittings2023-08-3106815886core:OfficeEquipment2023-08-3106815886core:AfterOneYear2023-08-3106815886core:WithinOneYear2023-08-3106815886core:ListedExchangeTraded2023-08-3106815886core:UnlistedNon-exchangeTraded2023-08-3106815886core:ShareCapital2023-08-3106815886core:SharePremium2023-08-3106815886core:RevaluationReserve2023-08-3106815886core:OtherReservesSubtotal2023-08-3106815886core:RetainedEarningsAccumulatedLosses2023-08-3106815886core:AfterOneYear2024-04-232025-03-3106815886core:WithinOneYear2024-04-232025-03-3106815886core:Non-currentFinancialInstrumentscore:CostValuation2024-04-232025-03-3106815886core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-04-232025-03-3106815886core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-04-232025-03-3106815886core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-04-232025-03-3106815886core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-04-232025-03-3106815886core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-04-232025-03-3106815886core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-04-232025-03-3106815886core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-04-232025-03-3106815886core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-04-232025-03-3106815886core:Non-currentFinancialInstrumentscore:CostValuation2025-03-3106815886core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-03-3106815886core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-03-3106815886core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-03-3106815886core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-03-3106815886core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-03-3106815886core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-03-3106815886core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-03-3106815886core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-03-3106815886core:Non-currentFinancialInstrumentscore:CostValuation2024-04-2206815886core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-04-2206815886core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-04-2206815886core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-04-2206815886core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-04-2206815886core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-04-2206815886core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-04-2206815886core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-04-2206815886core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-04-2206815886bus:Director12024-04-232025-03-3106815886core:FurnitureFittingsToolsEquipment2024-04-2206815886core:FurnitureFittingsToolsEquipment2024-04-232025-03-3106815886core:FurnitureFittingsToolsEquipment2025-03-31

ORAL IMPLANTS LIMITED

Registered Number
06815886
(England and Wales)

Unaudited Financial Statements for the Period ended
31 March 2025

ORAL IMPLANTS LIMITED
Company Information
for the period from 23 April 2024 to 31 March 2025

Director

Marina George Kudiyirickal

Registered Address

29 Castle Street
Northwich
CW8 1BA

Registered Number

06815886 (England and Wales)
ORAL IMPLANTS LIMITED
Statement of Financial Position
31 March 2025

Notes

31 Mar 2025

22 Apr 2024

£

£

£

£

Fixed assets
Tangible assets556,0607,302
56,0607,302
Current assets
Debtors7206,311223,324
Cash at bank and on hand1,31294,347
207,623317,671
Creditors amounts falling due within one year8(37,790)(53,555)
Net current assets (liabilities)169,833264,116
Total assets less current liabilities225,893271,418
Provisions for liabilities9(4,018)(1,507)
Net assets221,875269,911
Capital and reserves
Called up share capital100100
Profit and loss account221,775269,811
Shareholders' funds221,875269,911
The financial statements were approved and authorised for issue by the Director on 30 September 2025, and are signed on its behalf by:
Marina George Kudiyirickal
Director
Registered Company No. 06815886
ORAL IMPLANTS LIMITED
Notes to the Financial Statements
for the period ended 31 March 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number is 06815886 and the registered office address is 29 Castle Street, Northwich, Cheshire, CW8 1BA.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Basis of preparation
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
Functional and presentation currency
The financial statements are presented in sterling and this is the functional currency of the company.
Going concern
The company meets its day to day working capital requirements through the continued support of its directors.
Judgements and key sources of estimation uncertainty
In the application of the company's accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. These critical accounting judgements and estimations are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods. The critical judgements made by management that have a significant effect on the amounts recognised in the financial statements are described below.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts. Turnover includes revenue earned from rendering of dental practice services.
Revenue from rendering of services
Revenue from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
Operating leases
Where, substantially, all the risks and rewards of ownership of the asset do not transfer from the lessor to the company, the lease is treated as an operating lease. Rentals payable under operating leases are charged to the profit and loss account on a straight-line basis over the period of the lease.
Employee benefits
Short-term employee benefits are measured at the undiscounted amount expected to be paid in exchange for the employee's services to the company. Where employees have accrued short-term benefits which the entity has not paid by the balance sheet date, an accrual is recognised within creditors: amounts falling due within one year together with an associated expense in profit or loss. The liabilities are classified as current obligations in the statement of financial position because they are expected to be settled wholly within twelve months after the end of the period.
Current taxation
Current tax is recognised in profit or loss, except for taxes related to revaluations of land and buildings which are recognised in other comprehensive income. Current tax represents the amount of tax payable (receivable) in respect of taxable profit (loss) for the current, or past, reporting periods. Current tax is measured at the amount expected to be paid (recovered) using the tax rates and laws which have been enacted, or substantively enacted, by the balance sheet date. Where payments to HM Revenue and Customs exceed liabilities owed, an asset is recognised to the extent of the amount of tax recoverable.
Deferred tax
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Intangible assets
Intangible assets are stated at cost less accumulated amortisation and accumulated impairment losses. The assets are reviewed for impairment if the above factors indicate that the carrying amount may be impaired. Amortisation is included in 'administrative expenses' in the profit and loss account.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

Straight line (years)
Plant and machinery4
Fixtures and fittings4
Vehicles4
Office Equipment4
Cash and cash equivalents
Cash and cash equivalents comprise cash at bank and on hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less. Bank overdrafts are disclosed separately. For the purpose of the cash flow statement, bank overdrafts form an integral part of the company's cash management and are included as a component of cash and cash equivalents.
Financial instruments
A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at transaction price and measured at amortised cost using the effective interest method. Where investments in non-derivative financial instruments are publicly traded, or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value through profit and loss. All other investments are subsequently measured at cost less impairment. Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financial transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised. Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised. Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
Government grants or assistance
The company received in-kind support valued at £9,369.50 under the UK Subsidy Control Act 2022 (Minimal Financial Assistance). Services were provided by Manchester Metropolitan University through the Cheshire Innovation Network. The value has been recognised as both other income and a corresponding administrative expense in the profit and loss account.
2.Average number of employees
Average number of employees, including directors

20252024
Average number of employees during the year66
3.Intangible assets

Goodwill

Total

££
Cost or valuation
At 23 April 24215,000215,000
At 31 March 25215,000215,000
Amortisation and impairment
At 23 April 24215,000215,000
At 31 March 25215,000215,000
Net book value
At 31 March 25--
At 22 April 24--
4.Useful life of intangible assets
Goodwill relates to internally generated goodwill and was amortised over a period of 5 years. The goodwill balance was fully amortised, and no amount remains in the financial statements as at the reporting date.
5.Tangible fixed assets

Plant & machinery

Vehicles

Fixtures & fittings

Office Equipment

Total

£££££
Cost or valuation
At 23 April 2419,391-55,3444,40379,138
Additions19,82641,5231,7405,18968,278
At 31 March 2539,21741,52357,0849,592147,416
Depreciation and impairment
At 23 April 2418,749-50,4072,68071,836
Charge for year2,37010,2635,1291,75819,520
At 31 March 2521,11910,26355,5364,43891,356
Net book value
At 31 March 2518,09831,2601,5485,15456,060
At 22 April 24642-4,9371,7237,302
6.Impairment of tangible fixed assets
Tangible fixed assets are reviewed for indicators of impairment at each reporting date. If such indicators are identified, the recoverable amount is estimated, and an impairment loss is recognised where the carrying amount exceeds the recoverable amount. No such indicators were noted during the year.
7.Debtors: amounts due within one year

2025

2024

££
Trade debtors / trade receivables4,0563,498
Amounts owed by group undertakings196,084218,497
Other debtors6,1711,329
Total206,311223,324
At the balance sheet date, other debtors comprised the following: Prepayments: £4,211 PAYE payable (Debit balance): £1,959
8.Creditors: amounts due within one year

2025

2024

££
Trade creditors / trade payables8,413-
Bank borrowings and overdrafts7-
Taxation and social security-37,124
Other creditors29,37016,431
Total37,79053,555
At the balance sheet date, other creditors comprised the following: Accruals: £977.46 Pension payable: £513 (paid in the month of April 2025) Directors' loan account: £27,393
9.Provisions for liabilities

2025

2024

££
Net deferred tax liability (asset)4,0181,507
Total4,0181,507
10.Share capital
At 31 March 2025, the issued share capital consists of one ordinary share of £100 (2024: £100). The share carries equal voting rights, rights to dividends, and rights to capital on winding up. It is wholly owned by the parent company, LADYWELL ENTERPRISES LIMITED.
11.Related party transactions
The Company is a wholly-owned subsidiary of Ladywell Enterprises Limited and whose registered office is 74 Williams Lane, Fulwood, Preston, England, PR2 9UT. During the year, the Company entered into transactions with its holding company Ladywell Enterprises Limited in the ordinary course of business. These transactions were carried out on normal commercial terms. At 31 March 2025: The Company was owed £196,083.99 (2024: £ 218,497.37) which is included within other debtors. Also, the company entered into a lease agreement for its trading premises with Mrs. Marina George Kudiyirickal, a director of the company. The annual rent is £13,800, payable monthly in advance. There were no amounts outstanding at the year end. All outstanding balances with related parties are unsecured, interest-free, and have no fixed date for repayment. No guarantees have been given or received in respect of these balances.
12.Controlling party
The company is a wholly owned subsidiary of Ladywell Enterprises Limited, which is the immediate and ultimate controlling party.
13.Change in reporting period and impact on comparability
As the current accounting period is the period ended 31 March 2025 and the previous year was year ending 22 April 2024, the monetary amounts for these are not comparable.